PTQ® IMPLANTS

PTQ® Implants are indicated for trans-sphincteric implantation in the Internal Anal Sphincter (IAS) for the treatment of faecal incontinence due to a weak or disrupted internal anal sphincter. PTQ fills the gap between conservative and invasive treatments and provides results in the short-term and beyond.

SAFE. SIMPLE. RESTORATIVE.

SAFE
• Used to treat faecal incontinence since 2002
• Technology based on 20 years of experience with Macroplastique®, the leading urinary bulking agent in Europe
• Treatment is generally well-tolerated by patients
• Complications typically minor and transient

SIMPLE
• Minimally invasive
• Immediate results
• Simple technique
• Local anaesthesia
• Outpatient / day case procedure

RESTORATIVE
• Up to 95% of patients show a significant improvement in incontinence scores\textsuperscript{1,2}
• Provides sustainable improvement for 12-24 months\textsuperscript{1,10}
• Improves patient quality of life\textsuperscript{1,3, 6, 11}
• Reinjection is safe and effective\textsuperscript{4}
• Helps improve anal asymmetry index which may be linked to increased maximum resting anal canal pressures\textsuperscript{1}

"Considering the complexity of anal incontinence and the need to provide adequate care ... injection of a bulking agent is an attractive minimally invasive option."\textsuperscript{1}

"Injection of [PTQ Implants] provided a marked improvement in fecal continence and quality of life in patients with internal sphincter dysfunction, despite the presence of pudendal neuropathy"\textsuperscript{4}
"BENEFICIAL EFFECTS OF [PTQ] IMPLANTS CAN CONTINUE FOR UP TO 4 YEARS."²

CLINICAL HIGHLIGHTS

EFFECTIVE IN THE SHORT TERM AND BEYOND
- Majority of patients cured/improved following PTQ treatment¹,¹¹
- Studies indicate that the maximum improvement typically occurs between 3 and 12 months¹, ⁴, ⁵, ⁸-¹¹
- Significant improvements over baseline are maintained at 18 or 24 months², ⁶-⁸, ¹⁰
- At 28 month median follow-up:
  - 70% of patients were continent and extremely satisfied²
  - 95% of patients maintained continence from 6 weeks²

IMPROVEMENTS IN QUALITY OF LIFE
- Significant improvements in all Quality of Life (QoL) domains in clinical studies (follow-up range of 6 weeks - 42 months)¹, ⁴, ⁶, ¹⁰, ¹¹
- Significant improvements in SF-12 physical health scale at 12 months³, ⁴
- Significant improvements in SF-36 physical health and social function scores at 18 months⁷
- Significant improvements in resting and squeeze pressures²

"There was a significant improvement in all domains of the faecal incontinence quality of life scale in the PTQ group at 6 weeks and 6 months ... By contrast there was no improvement in any domain ... in the Durasphere group ..."³

For complete instructions for use, storage, warnings, indications, contraindications, precautions, adverse reactions and disclaimer of warranties, please refer to the insert accompanying each PTQ product. PTQ is a registered trademark. PTQ is manufactured by Uroplasty, LLC. Models are for illustrative purpose only. ©2018 LABORIE. All rights reserved.

<table>
<thead>
<tr>
<th>CATALOG NUMBER</th>
<th>PRODUCT DESCRIPTION</th>
<th>PROCEDURE REQUIREMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTQ-2.5</td>
<td>2.5 ml unit</td>
<td>3 units</td>
</tr>
<tr>
<td>AD</td>
<td>Reusable Administration Device Includes syringe adapter</td>
<td>1 device</td>
</tr>
<tr>
<td>PRN-090</td>
<td>Rigid Needle 18 gauge x 90 mm long</td>
<td>1 needle</td>
</tr>
</tbody>
</table>